Add-on Sacubitril/Valsartan Therapy Induces Left Ventricular Remodeling in Non-responders to Cardiac Resynchronization Therapy to a Similar Extent as in Heart Failure Patients Without Resynchronization.

The introduction of sacubitril/valsartan (SV), a new therapeutic class of agents acting on the renin–angiotensin system (RAS) and the neutral endopeptidase system (ARNI, angiotensin receptor neprilysin inhibitor) is considered a highly significant development in HF therapy.

also in 132,142 other papers